Marizyme, Inc. (MRZM)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 26.67 Million USD | 25.44% |
| 2022 | 21.26 Million USD | 16.15% |
| 2021 | 18.3 Million USD | 919.47% |
| 2020 | 1.79 Million USD | 564.62% |
| 2019 | 270.21 Thousand USD | 531.65% |
| 2018 | 42.78 Thousand USD | -93.45% |
| 2017 | 652.67 Thousand USD | 124.2% |
| 2016 | 291.1 Thousand USD | -93.21% |
| 2015 | 4.28 Million USD | 95.38% |
| 2014 | 2.19 Million USD | 69.44% |
| 2013 | 1.29 Million USD | -94.46% |
| 2012 | 23.36 Million USD | -3.78% |
| 2011 | 24.28 Million USD | 62867.78% |
| 2010 | 38.56 Thousand USD | 125.83% |
| 2009 | 17.07 Thousand USD | -45.01% |
| 2008 | 31.05 Thousand USD | 1728.02% |
| 2007 | 1699.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 32.4 Million USD | 21.47% |
| 2024 Q2 | 30.91 Million USD | -4.59% |
| 2023 FY | 26.67 Million USD | 25.44% |
| 2023 Q2 | 29.71 Million USD | 28.97% |
| 2023 Q4 | 26.67 Million USD | -54.69% |
| 2023 Q3 | 58.86 Million USD | 98.14% |
| 2023 Q1 | 23.03 Million USD | 8.33% |
| 2022 Q1 | 19.75 Million USD | 7.92% |
| 2022 Q2 | 22.95 Million USD | 16.15% |
| 2022 Q4 | 21.26 Million USD | -6.64% |
| 2022 FY | 21.26 Million USD | 16.15% |
| 2022 Q3 | 22.77 Million USD | -0.75% |
| 2021 Q4 | 18.3 Million USD | 38.05% |
| 2021 FY | 18.3 Million USD | 919.47% |
| 2021 Q2 | 2.79 Million USD | 61.93% |
| 2021 Q1 | 1.72 Million USD | -3.82% |
| 2021 Q3 | 13.26 Million USD | 374.15% |
| 2020 Q4 | 1.79 Million USD | 285.3% |
| 2020 FY | 1.79 Million USD | 564.62% |
| 2020 Q2 | 441.63 Thousand USD | 11.67% |
| 2020 Q1 | 395.5 Thousand USD | 46.36% |
| 2020 Q3 | 466.11 Thousand USD | 5.54% |
| 2019 FY | 270.21 Thousand USD | 531.65% |
| 2019 Q1 | 95.41 Thousand USD | 123.03% |
| 2019 Q3 | 72.58 Thousand USD | -65.87% |
| 2019 Q2 | 212.66 Thousand USD | 122.88% |
| 2019 Q4 | 270.21 Thousand USD | 272.29% |
| 2018 Q3 | 80.19 Thousand USD | 243.22% |
| 2018 Q1 | 660 Thousand USD | 1.12% |
| 2018 FY | 42.78 Thousand USD | -93.45% |
| 2018 Q2 | 23.36 Thousand USD | -96.46% |
| 2018 Q4 | 42.78 Thousand USD | -46.65% |
| 2017 Q4 | 652.67 Thousand USD | 161.07% |
| 2017 FY | 652.67 Thousand USD | 124.2% |
| 2017 Q3 | 250 Thousand USD | 8.7% |
| 2017 Q2 | 230 Thousand USD | -8.0% |
| 2017 Q1 | 250 Thousand USD | 0.0% |
| 2016 FY | 291.1 Thousand USD | -93.21% |
| 2015 FY | 4.28 Million USD | 95.38% |
| 2014 FY | 2.19 Million USD | 69.44% |
| 2013 FY | 1.29 Million USD | -94.46% |
| 2013 Q4 | 1.29 Million USD | -92.32% |
| 2013 Q3 | 16.87 Million USD | -4.49% |
| 2013 Q2 | 17.66 Million USD | 6.49% |
| 2013 Q1 | 16.58 Million USD | -29.02% |
| 2012 FY | 23.36 Million USD | -3.78% |
| 2012 Q4 | 23.36 Million USD | 4.18% |
| 2012 Q3 | 22.42 Million USD | -10.99% |
| 2012 Q2 | 25.19 Million USD | -6.23% |
| 2012 Q1 | 26.87 Million USD | 4.8% |
| 2011 FY | 24.28 Million USD | 62867.78% |
| 2011 Q4 | 25.64 Million USD | -1.97% |
| 2011 Q3 | 26.15 Million USD | 3.3% |
| 2011 Q2 | 25.32 Million USD | 4.26% |
| 2011 Q1 | 24.28 Million USD | 4330.55% |
| 2010 Q1 | 38.56 Thousand USD | -3.69% |
| 2010 Q2 | 20.5 Thousand USD | -46.85% |
| 2010 Q3 | 36.65 Thousand USD | 78.78% |
| 2010 Q4 | 548.15 Thousand USD | 1395.63% |
| 2010 FY | 38.56 Thousand USD | 125.83% |
| 2009 FY | 17.07 Thousand USD | -45.01% |
| 2009 Q4 | 40.04 Thousand USD | -86.75% |
| 2009 Q3 | 302.33 Thousand USD | 1172.38% |
| 2009 Q2 | 23.76 Thousand USD | 39.12% |
| 2009 Q1 | 17.07 Thousand USD | -42.21% |
| 2008 Q1 | 31.05 Thousand USD | 86.22% |
| 2008 Q2 | 39.22 Thousand USD | 26.3% |
| 2008 Q4 | 29.55 Thousand USD | -18.57% |
| 2008 FY | 31.05 Thousand USD | 1728.02% |
| 2008 Q3 | 36.29 Thousand USD | -7.48% |
| 2007 Q2 | 6534.00 USD | 0.0% |
| 2007 Q3 | 11.83 Thousand USD | 81.07% |
| 2007 Q4 | 16.67 Thousand USD | 40.97% |
| 2007 FY | 1699.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -97139.496% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -181.808% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 63.191% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -3198.208% |
| Rebus Holdings, Inc. | 5.24 Million USD | -408.884% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 54.798% |
| Qrons Inc. | 1.48 Million USD | -1691.864% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -2075.455% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 64.394% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -59582.547% |
| Skye Bioscience, Inc. | 14.07 Million USD | -89.563% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 49.956% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -178.393% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -6227.736% |
| SQZ Biotechnologies Company | 50.03 Million USD | 46.69% |
| Intellipharmaceutics International Inc. | 12 Million USD | -122.135% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -592.619% |
| Mesoblast Limited | 188.44 Million USD | 85.844% |
| Genus plc | 485 Million USD | 94.5% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -356.571% |
| Pharming Group N.V. | 244.07 Million USD | 89.071% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1227.064% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -960.105% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -601.992% |
| ContraFect Corporation | 32.53 Million USD | 17.999% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1246.369% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -596.922% |
| IMV Inc. | 37.93 Million USD | 29.676% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -126.484% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1648920.567% |
| ONE Bio Corp. | 27.49 Million USD | 2.983% |
| Accustem Sciences Inc. | 1.07 Million USD | -2371.715% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 65.543% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -1161.222% |
| Q BioMed Inc. | 8.13 Million USD | -227.996% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 67.835% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -418.374% |
| Biomind Labs Inc. | 1.49 Million USD | -1680.028% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 77.531% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -195.014% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -44.95% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1760.411% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -18673.152% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -13163.843% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -364.263% |
| GB Sciences, Inc. | 5.41 Million USD | -392.394% |
| Alpha Cognition Inc. | 7.16 Million USD | -272.318% |
| HST Global, Inc. | 593.59 Thousand USD | -4393.94% |
| CSL Limited | 18.62 Billion USD | 99.857% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -2018.477% |
| Halberd Corporation | 728.71 Thousand USD | -3560.631% |
| Enzolytics Inc. | 365.26 Million USD | 92.697% |
| Agentix Corp. | 2.51 Million USD | -962.542% |
| Resverlogix Corp. | 67.39 Million USD | 60.419% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -3080.481% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 94.005% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1456.343% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -7.798% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -124.107% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -627.818% |
| AVAX Technologies, Inc. | 3.99 Million USD | -567.937% |
| Zenith Capital Corp. | 27.56 Thousand USD | -96659.806% |
| Genscript Biotech Corporation | 1.32 Billion USD | 97.988% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -11077.567% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -614.342% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -3818.093% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -883.748% |
| Kadimastem Ltd | 3.5 Million USD | -661.105% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -39756.73% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 46.929% |
| BioStem Technologies, Inc. | 15.9 Million USD | -67.723% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -5640.428% |
| LadRx Corporation | 2.2 Million USD | -1112.241% |
| Cell Source, Inc. | 15.8 Million USD | -68.762% |
| Regen BioPharma, Inc. | 5.45 Million USD | -388.78% |
| Regen BioPharma, Inc. | 5.45 Million USD | -388.78% |
| NovAccess Global Inc. | 7.86 Million USD | -239.354% |
| Affymax, Inc. | 8.87 Million USD | -200.707% |
| Itoco Inc. | 1.65 Million USD | -1513.628% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1200.262% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -340.994% |
| Mobile Lads Corp. | 1.31 Million USD | -1930.892% |
| CytoDyn Inc. | 127.89 Million USD | 79.142% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -63719.017% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1603.02% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -141.512% |
| SYBLEU INC | 681.41 Thousand USD | -3814.764% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -337.17% |
| International Stem Cell Corporation | 5.27 Million USD | -405.509% |
| Bioxytran, Inc. | 3.24 Million USD | -720.917% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -4162.596% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -477.756% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 34.931% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -19.81% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1217.067% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -386.961% |
| Neutra Corp. | 973.52 Thousand USD | -2640.104% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 8.062% |
| PureTech Health plc | 125.58 Million USD | 78.759% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -610.003% |
| IXICO plc | 1.9 Million USD | -1303.769% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -29.942% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 74.182% |
| CSL Limited | 18.62 Billion USD | 99.857% |
| Cellectis S.A. | 249.36 Million USD | 89.303% |